Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Immunic AG

Immunic AG is a start-up biotech company founded in April 2016 and focused on the development of immune modulators to block TH17- and TH1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and RORgt (IMU-366 program) relevant to diseases such as Crohn’s disease and psoriasis. The final aim is to develop these drug candidates to clinical proof of concept. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors. *


Period Start 2016-04-12 established
  Group Immunic (Group)
Products Industry small-molecule drug
  Industry 2 immunotherapy
Persons Person Vitt, Daniel (Immunic 201701– CEO before 4SC 1997–201612 CSO + Co-Founder before Univ Würzburg)
  Person 2 Gröppel, Manfred (Immunic 201604– COO + Co-Founder before 4SC 200901 Business Development)
Region Region Martinsried
  Country Germany
  Street 19a Am Klopferspitz
  City 82152 Martinsried
  Tel +49-89-700763-0
    Address record changed: 2016-10-01
Basic data Employees A: 1 to 10 (2018-12-20)
    * Document for �About Section�: Immunic AG. (9/28/16). "Press Release: Immunic Acquires 4SC’s Immunology Portfolio". Planegg-Martinsried.
Record changed: 2019-04-18


Picture [LSUS] – The Business Web Portal 600x60px

More documents for Immunic (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px

» top